title: Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.
abstract: The large human efficacy trail in Thailand, RV144, was concluded in the summer of 2009. This is the first Phase III trial to show limited, but significant, efficacy in preventing HIV acquisition. This trial represents the first sign that a preventive vaccine for HIV may be feasible. The vaccine regimen tested in Thailand consisted of priming with a Canarypox vector carrying three synthetic HIV genes. The priming was followed by booster inoculations with two recombinant envelope proteins from HIV, clade B and E. The need to understand the role in protection from HIV acquisition of the new responses, induced by this vaccine combination, has brought together many researchers with the common goal of improving the development of a safe and effective vaccine for HIV.
authors.affiliation: Animal Models and Retroviral Vaccine Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Monica
authors.initials: M
authors.lastname: Vaccari
authors.forename: Poonam
authors.initials: P
authors.lastname: Poonam
authors.forename: Genoveffa
authors.initials: G
authors.lastname: Franchini
mesh_terms: D016915:AIDS Vaccines / Q000009:adverse effects / Q000276:immunology*; D028121:Canarypox virus / Q000235:genetics; D017326:Clinical Trials, Phase III as Topic; D005822:Genetic Vectors; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods; D013785:Thailand; D014611:Vaccination / Q000379:methods
chemical_list: D016915:AIDS Vaccines
references.citation: J Infect Dis. 1995 Jun;171(6):1623-7
references.pmid: 7769304
references.citation: Vaccine. 2004 Jan 26;22(5-6):597-606
references.pmid: 14741150
references.citation: Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S75-88
references.pmid: 15285707
references.citation: Virology. 1997 May 26;232(1):98-104
references.pmid: 9185593
references.citation: AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S325-31
references.pmid: 9814961
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Nov 1;19(3):289-95
references.pmid: 9803972
references.citation: J Virol. 2006 Apr;80(8):3732-42
references.pmid: 16571790
references.citation: J Infect Dis. 1998 May;177(5):1230-46
references.pmid: 9593008
references.citation: AIDS. 1997;11 Suppl A:S127-37
references.pmid: 9451976
references.citation: Vaccine. 1995 Apr;13(6):539-49
references.pmid: 7483774
references.citation: J Infect Dis. 1996 Nov;174(5):977-85
references.pmid: 8896498
references.citation: JAMA. 1994 Aug 10;272(6):475-80
references.pmid: 7913731
references.citation: J Virol. 2003 Oct;77(20):11220-31
references.pmid: 14512570
references.citation: Asian Pac J Allergy Immunol. 1985 Dec;3(2):195-9
references.pmid: 2866780
references.citation: Science. 1983 May 20;220(4599):868-71
references.pmid: 6189183
references.citation: Curr Opin Biotechnol. 1997 Oct;8(5):573-7
references.pmid: 9353230
references.citation: J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):468-75
references.pmid: 17496560
references.citation: Mol Biol Evol. 2010 Feb;27(2):417-25
references.pmid: 19864468
references.citation: AIDS Res Hum Retroviruses. 1996 Mar 20;12(5):407-8
references.pmid: 8882320
references.citation: Tissue Antigens. 2004 Sep;64(3):251-6
references.pmid: 15304005
references.citation: J Infect Dis. 1996 Jan;173(1):52-9
references.pmid: 8537682
references.citation: J Infect Dis. 2004 Sep 1;190(5):903-7
references.pmid: 15295694
references.citation: AIDS. 1997 May;11(6):819-20
references.pmid: 9143616
references.citation: J Virol. 2002 Jan;76(1):292-302
references.pmid: 11739694
references.citation: Nat Med. 1995 Apr;1(4):321-9
references.pmid: 7585061
references.citation: JAMA. 1994 Aug 10;272(6):488-9
references.pmid: 8040986
references.citation: J Immunol. 2002 Feb 15;168(4):1847-53
references.pmid: 11823518
references.citation: Virology. 1999 Dec 5;265(1):1-9
references.pmid: 10603312
references.citation: Vaccine. 2002 May 6;20(15):1905-8
references.pmid: 11983242
references.citation: J Infect Dis. 2001 May 1;183(9):1343-52
references.pmid: 11294665
references.citation: Dev Biol Stand. 1995;84:159-63
references.pmid: 7796949
references.citation: AIDS Res Hum Retroviruses. 1996 Jul 20;12(11):985-92
references.pmid: 8827214
references.citation: Vaccine. 2001 Feb 28;19(15-16):2080-91
references.pmid: 11228380
references.citation: J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):48-55
references.pmid: 17909315
references.citation: J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):124-34
references.pmid: 15671796
references.citation: AIDS Res Hum Retroviruses. 2004 Jun;20(6):642-4
references.pmid: 15242541
references.citation: Vaccine. 1992;10(1):8-9
references.pmid: 1311489
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 15;20(5):488-94
references.pmid: 10225232
references.citation: Vaccine. 2009 Feb 11;27(7):1136-40
references.pmid: 19071176
references.citation: J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1385-92
references.pmid: 15483468
references.citation: J Infect Dis. 2004 Aug 15;190(4):702-6
references.pmid: 15272397
references.citation: AIDS. 1998;12 Suppl B:S155-61
references.pmid: 9679641
references.citation: J Virol. 2005 Oct;79(19):12321-31
references.pmid: 16160159
references.citation: AIDS. 2000 Jul 7;14(10):1365-74
references.pmid: 10930151
references.citation: Science. 2004 Jan 16;303(5656):316
references.pmid: 14726576
references.citation: N Engl J Med. 2009 Dec 3;361(23):2209-20
references.pmid: 19843557
references.citation: J Infect Dis. 2005 Mar 1;191(5):654-65
references.pmid: 15688278
references.citation: Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S99-104
references.pmid: 15285709
references.citation: Virology. 2002 Dec 5;304(1):125-34
references.pmid: 12490410
references.citation: J Virol. 1999 Jun;73(6):4640-50
references.pmid: 10233923
references.citation: AIDS Res Hum Retroviruses. 1995 Aug;11(8):909-20
references.pmid: 7492438
references.citation: Lancet. 2008 Nov 29;372(9653):1881-1893
references.pmid: 19012954
references.citation: AIDS. 1998 Dec 24;12(18):2407-15
references.pmid: 9875578
references.citation: Nature. 1990 Jun 14;345(6276):622-5
references.pmid: 2190095
references.citation: J Virol. 1990 Jun;64(6):2653-9
references.pmid: 2186175
references.citation: J Infect Dis. 2006 Dec 15;194(12):1661-71
references.pmid: 17109337
references.citation: Expert Rev Vaccines. 2008 Apr;7(3):311-7
references.pmid: 18393601
references.citation: Science. 2004 Jul 9;305(5681):177-80; author reply 177-80
references.pmid: 15247455
references.citation: J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):9-17
references.pmid: 12514409
references.citation: AIDS Res Hum Retroviruses. 1995 Mar;11(3):373-81
references.pmid: 7598771
references.citation: AIDS Alert. 2001 Nov;16(11):141-2, 147
references.pmid: 11692665
references.citation: Dev Biol Stand. 1995;84:165-70
references.pmid: 7796950
references.citation: PLoS Med. 2008 Aug 12;5(8):e173
references.pmid: 18700814
references.citation: AIDS. 1995 Dec;9(12):1313-22
references.pmid: 8605050
references.citation: Dev Biol Stand. 1994;82:65-9
references.pmid: 7958484
references.citation: Vaccine. 1999 Oct 1;17 Suppl 2:S65-70
references.pmid: 10506410
references.citation: AIDS. 1991 Jun;5(6):639-54
references.pmid: 1883539
references.citation: AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1175-89
references.pmid: 11522187
references.citation: IAVI Rep. 2009 Sep-Oct;13(5):4-5, 7-13, 17
references.pmid: 20214263
references.citation: J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1160-5
references.pmid: 15319676